New AI vaccine developed
Vaxin has now developed a vaccine that can be rapidly produced and mass administered. This vaccine was recently featured at the Immunotherapeutics & Vaccine Summit in Boston.
Kent Van Kampen, Vaxin’s COO and an authority on vaccine development: “Our vaccine uses a neutered cold virus to carry a tiny snippet of influenza DNA, rather than the entire influenza virus,” Van Kampen said.
“When the immune system responds, it actually learns how to be immune to the target disease – avian influenza in this case.”
This vaccine has been shown to provide excellent protection when administered to poultry before hatching. Vaxin has utilised these advances to develop a version of the vaccine that will soon be tested in humans.